## AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

- 1. (Canceled)
- 2. (Currently amended) A method for reducing sepsis-associated lethality in a mammal that develops with sepsis, the method comprising the step of:
  - (a) administering an amount of isolated or purified tissue cytotoxic factor II (TCF-II) effective to reduce sepsis-associated lethality, wherein TCF-II is administered before onset of sepsis in the mammal.
- 3. (Previously presented) The method of claim 2, wherein the TCF-II is administered intravenously, intramuscularly or subcutaneously.
- 4. (Previously presented) The method of claim 2, wherein the TCF-II is produced recombinantly.
- 5. (Previously presented) The method of claim 2, comprising the additional step, prior to step (a), of

purifying an amount of TCF-II effective to treat sepsis.

- 6-7. (Canceled)
- 8. (Previously presented) The method of claim 2, wherein the TCF-II is administered to the mammal in conjunction with a pH conditioner, buffer or stabilizer.
- 9. (Previously presented) The method of claim 2, wherein the amount of TCF-II is from about 0.6 mg to about 600 mg of TCF-II.

Amendment and Response Serial No. 09/423,905 Page 3 of 7

10. (Previously presented) The method of claim 9, wherein the amount of TCF-II is from about 6 mg to about 60 mg of TCF-II.

11-35. (Canceled)